CS20AT04 (allogenic bone marrow derived mesenchymal stem cell) ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
49全身性エリテマトーデス1

49. 全身性エリテマトーデス


臨床試験数 : 946 薬物数 : 722 - (DrugBank : 186) / 標的遺伝子数 : 117 - 標的パスウェイ数 : 199
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04835883
(ClinicalTrials.gov)
September 26, 20196/4/2021Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus PatientsOpen-label, Single-arm, 24-week Investigator Study to Evaluate the Efficacy and Safety of CS20AT04 (HLA-haplo Matched Allogenic Bone Marrow-Derived Stem Cells) Administered in Patients With Lupus Nephritis or Lupus CytopeniaSystemic Lupus ErythematosusBiological: CS20AT04 (allogenic bone marrow derived mesenchymal stem cell)Hanyang University Seoul HospitalCorestem, Inc.;Ministry of Health & Welfare, KoreaRecruiting18 Years70 YearsAll10Phase 2Korea, Republic of